For instance, EGFR inhibitors like erlotinib[16] and gefitinib[17] have proven effective in treating non-small cell lung cancer with EGFR mutations, showcasing the precision of TKIs in addressing specific cancer subtypes. Here, EGFR is linked to non-small cell lung carcinoma.